Bio News
SK Biopharmaceuticals will acquire 1ST-104, a Parkinson’s disease drug candidate, from 1ST Biotherapeutics. The total value of the agreement is $314.8 million (approximately 421.8 billion won).
1ST Biotherapeutics will receive an upfront payment of $1.8 million and short-term milestone payments, while SK Biopharmaceuticals will also make a $2.2 million equity investment.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
